Memantine – Mechanism of Action | Psychopharmacology | Clinical Application

Posted on:October 27, 2022
Last Updated: March 20, 2023
Time to read: 10 minutes

Memantine is a low-affinity voltage-dependent non-competitive NMDA receptor antagonist that is approved for treating moderate-to-severe Alzheimer’s disease (AD). [Reisberg et al 2003]

Memantine is a primary aliphatic amine with a three-ring structure that binds to the magnesium cation channel of the NMDA receptor.

  • Memantine is available as an oral solution, a tablet, and an extended-release capsule.
  • Memantine can be prescribed independently or with an acetylcholinesterase inhibitor such as donepezil, rivastigmine, or galantamine. [Allgaier and Allgaier 2014]